Biomark sets 2025 to 2026 cancer test milestones

Executive Summary

• Biomark Diagnostics Inc. reported fiscal year 2025 highlights, including the completion of a $4.26-million private placement and the securing of over $365,000 in non-dilutive grant funding.
• The company outlined a strategic roadmap for 2025-2026, targeting the completion of a pivotal 6,000-patient lung cancer clinical trial in Q3 2025 and the launch of commercial operations for its lung cancer assay in Quebec by Q3-Q4 2025.
• Operational progress includes advancing AI-powered diagnostic assays for multiple cancers, initiating ISO 15189:2022 certification (targeted for Q4 2025), and preparing for CLIA certification to enable U.S. commercialization in early 2026.

Key Details

• Financing: Completed a $4.26-million private placement with participation from North American and European investors.
• Grant Funding: Secured over $365,000 in non-dilutive funding from partners including NRC-IRAP, Mitacs, Research Manitoba, and the City of Quebec.
• Financial Health: Achieved an 18% reduction in liabilities, maintained a lean monthly burn rate, and tripled current assets.
• Pipeline & Technology: Advanced a pipeline of AI-powered diagnostic assays for Non-Small Cell Lung Cancer (NSCLC), breast cancer, glioblastoma, and neuroendocrine tumours (NETs), integrating large language models (LLMs) and multitask deep learning.
• Certifications & Commercialization:
  • Initiated ISO 15189:2022 certification process, with completion targeted for Q4 2025.
  • Advanced preparations for CLIA certification to support U.S. commercialization by early 2026.
  • Began discussions on a U.S. reimbursement strategy.
• 2025-2026 Milestones:
  • Q2 2025: Double laboratory capacity via equipment installation and workflow optimization; expand lab personnel to support higher testing volumes and CRO services.
  • Q3 2025: Complete and publish results from the pivotal 6,000-patient lung cancer clinical trial.
  • Q3-Q4 2025: Launch commercial operations for the lung cancer assay in Quebec.
  • Q4 2025: Finalize ISO 15189 certification.
  • Early 2026: Secure CLIA certification and commence U.S. diagnostic service rollout.
• Collaborations: Strengthened engagements with AstraZeneca, the University of Maryland, and Ohio State University; supported a pan-European IHI Bridges proposal; initiated relationships with U.S.-based cancer screening centres.

Notable Quotes

• "Our team remained focused on disciplined execution, data-driven strategy and delivering tangible value," said Rashid Bux, Biomark's chief executive officer. "That focus earned us the continued support of investors who recognized the significance of our milestones in a tough market."